We are live on ! Find out more

CGC

Canopy Growth

CGC

Market cap $392M

0.9277 USD

-0.0023

0.25%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

0.9300

+0.0023

0.25%

1 day

-0.25%

5 days

-5.27%

1 month

-7.23%

3 months

-8.15%

6 months

-13.3%

Year to date

-22.04%

1 year

-33.26%

5 years

-99.38%

10 years

-99.67%

About: Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.

Employees: 1,128

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 45.3%

Neutral 37.7%

Negative 17%

Canopy Growth Broadens Australian Medical Cannabis Portfolio With New Formats and Formulations

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced a broadening of its medical cannabis portfolio in Australia across its Spectrum Therapeutics, Spectrum Therapeutics Reserve, 7ACRES, Tweed and Twd. brands. The expansion introduces two new product formats, and new formulations within its existing oil and softgel ranges.

Canopy Growth Broadens Australian Medical Cannabis Portfolio With New Formats and Formulations

The Motley Fool

Canopy Growth's Revenue Grew 13% Last Quarter. Investors Barely Reacted.

Canopy Growth's revenue increased 13% year over year in its most recent fiscal quarter. Adjusted gross margin improved, while EBITDA losses narrowed sharply.

Canopy Growth's Revenue Grew 13% Last Quarter. Investors Barely Reacted.

The Motley Fool

Should You Buy Canopy Growth Stock on the Rebound?

Canopy Growth is a large Canadian marijuana company. Over the past year, it has strengthened its financial position and made an acquisition.

Should You Buy Canopy Growth Stock on the Rebound?

The Motley Fool

Better Cannabis Stock to Buy Right Now: Canopy Growth or Tilray Brands?

Tilray is seeing more revenue from beverages than from cannabis. Canopy's debt situation drags down its growth potential.

Better Cannabis Stock to Buy Right Now: Canopy Growth or Tilray Brands?

MarijuanaStocks

3 Top Marijuana Stocks to Watch in September 2026

The cannabis industry is entering September, and investors are once again searching for opportunities across the sector. After years of volatility, several marijuana companies are showing signs of stronger financial performance. Revenue is improving for some operators. Meanwhile, others are cutting costs, strengthening margins, and expanding internationally. That combination could put marijuana stocks back on investors' radar. However, this is no longer simply a story about rapid expansion. Investors are becoming more selective about which cannabis companies deserve their attention. Today, profitability matters. Cash flow matters. Additionally, investors want companies with strong brands and opportunities beyond their existing markets. International cannabis growth has become particularly important. Europe continues expanding its medical cannabis industry. As a result, Canadian producers are positioning themselves to capture growing international demand. Meanwhile, the United States remains an important potential catalyst. Changes to federal cannabis regulations could eventually reshape the industry's investment landscape.

3 Top Marijuana Stocks to Watch in September 2026

Zacks Investment Research

Cannabis Operator CGC Rises 15% in a Month: Time to Buy, Hold or Sell?

Canopy Growth's cannabis business is showing signs of a turnaround, with revenue growth, improving margins and a narrower EBITDA loss fueling its rally.

Cannabis Operator CGC Rises 15% in a Month: Time to Buy, Hold or Sell?

24/7 Wall Street

Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%: Here's Why TLRY Is Still Down 47% YTD

Shares of Tilray Brands (NASDAQ:TLRY) are up 6% to $4.75 Wednesday afternoon, participating in a broad bid for beaten-down speculative names.

Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%: Here's Why TLRY Is Still Down 47% YTD

MarijuanaStocks

Top Canadian Cannabis Stocks to Watch in August 2026

Canadian cannabis stocks are once again gaining attention as investors search for opportunities within the global marijuana industry. The sector has experienced significant changes since Canada legalized recreational cannabis in 2018. However, several leading companies have emerged stronger after years of restructuring, cost reductions, and increased competition.

Top Canadian Cannabis Stocks to Watch in August 2026

Canopy Growth Announces Mailing of Proxy Materials for 2026 Annual General and Special Meeting – Urges Shareholders to Vote Now

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced the Company has mailed (or mailed a notice of internet availability with respect to) its proxy statement and fiscal 2026 annual report to shareholders (collectively, the “Meeting Materials”) for its Annual General and Special Meeting of shareholders (the “Meeting”) sche.

Canopy Growth Announces Mailing of Proxy Materials for 2026 Annual General and Special Meeting – Urges Shareholders to Vote Now

The Motley Fool

Curaleaf Wants to Buy Aurora Cannabis for $272 Million. Is Canopy Growth the Next Marijuana Takeover Target?

Curaleaf's bid signals cannabis consolidation is accelerating. Canopy Growth could emerge as another takeover candidate.

Curaleaf Wants to Buy Aurora Cannabis for $272 Million. Is Canopy Growth the Next Marijuana Takeover Target?

See News Rankings

Price charts implemented using Lightweight Charts™